PDF(Pubmed)
Abstract：
Anxiety is implicated in the course and prognosis of alcohol use disorder (AUD); however, it is unclear how current AUD treatments affect the joint trajectories of anxiety and alcohol use. We used data from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study to examine the longitudinal relationship between subclinical anxiety symptoms and alcohol use during and following AUD treatment in adults with AUD and no comorbid anxiety disorders.
Univariate and parallel process growth models using five waves of COMBINE study data were analyzed from 865 adults randomized to medication (n = 429) or medication plus psychotherapy (n = 436). Weekly drinking quantity and average weekly anxiety symptoms were measured at baseline, mid-treatment, end-of-treatment, and three follow-up periods.
Significant positive associations of anxiety symptoms and drinking were found at mid-treatment and over time. Temporal associations revealed that higher mid-treatment anxiety predicted decreases in drinking over time. Baseline anxiety and drinking predicted mid-treatment anxiety and drinking. Only baseline anxiety predicted increases in drinking over time. Group differences revealed mid-treatment drinking predicted decreases in anxiety over time in the medication group.
Findings demonstrate the influence of subclinical anxiety on alcohol use during and up to one year after AUD treatment. Baseline anxiety symptoms may influence drinking behavior over the course of treatment. Findings suggest that greater attention to negative affect in AUD treatment is warranted even for those individuals who do have a comorbid anxiety disorder.
Univariate and parallel process growth models using five waves of COMBINE study data were analyzed from 865 adults randomized to medication (n = 429) or medication plus psychotherapy (n = 436). Weekly drinking quantity and average weekly anxiety symptoms were measured at baseline, mid-treatment, end-of-treatment, and three follow-up periods.
Significant positive associations of anxiety symptoms and drinking were found at mid-treatment and over time. Temporal associations revealed that higher mid-treatment anxiety predicted decreases in drinking over time. Baseline anxiety and drinking predicted mid-treatment anxiety and drinking. Only baseline anxiety predicted increases in drinking over time. Group differences revealed mid-treatment drinking predicted decreases in anxiety over time in the medication group.
Findings demonstrate the influence of subclinical anxiety on alcohol use during and up to one year after AUD treatment. Baseline anxiety symptoms may influence drinking behavior over the course of treatment. Findings suggest that greater attention to negative affect in AUD treatment is warranted even for those individuals who do have a comorbid anxiety disorder.
摘要：
背景：焦虑与酒精使用障碍（AUD）的病程和预后有关；然而，目前尚不清楚AUD治疗如何影响焦虑和饮酒的联合轨迹.我们使用来自酒精依赖的联合药物疗法和行为干预（COMBINE）研究的数据，以检查AUD治疗期间和之后的AUD患者的亚临床焦虑症状与酒精使用之间的纵向关系。
方法：使用五波COMBINE研究数据的单变量和平行过程生长模型，对865名随机接受药物治疗（n=429）或药物加心理治疗（n=436）的成年人进行分析。每周饮酒量和每周平均焦虑症状在基线测量，中期治疗，治疗结束,和三个随访期。
结果：在治疗中期和一段时间内发现焦虑症状和饮酒呈显著正相关。时间关联显示，随着时间的推移，较高的治疗中期焦虑预示着饮酒的减少。基线焦虑和饮酒预测治疗中期焦虑和饮酒。只有基线焦虑预测饮酒会随着时间的推移而增加。组差异显示，治疗中期饮酒可预测药物组的焦虑随着时间的推移而减少。
结论：研究结果表明，亚临床焦虑对AUD治疗后一年内饮酒的影响。基线焦虑症状可能会影响治疗过程中的饮酒行为。研究结果表明，即使对于患有共病焦虑症的个体，也有必要在AUD治疗中更多地关注负面影响。
方法：使用五波COMBINE研究数据的单变量和平行过程生长模型，对865名随机接受药物治疗（n=429）或药物加心理治疗（n=436）的成年人进行分析。每周饮酒量和每周平均焦虑症状在基线测量，中期治疗，治疗结束,和三个随访期。
结果：在治疗中期和一段时间内发现焦虑症状和饮酒呈显著正相关。时间关联显示，随着时间的推移，较高的治疗中期焦虑预示着饮酒的减少。基线焦虑和饮酒预测治疗中期焦虑和饮酒。只有基线焦虑预测饮酒会随着时间的推移而增加。组差异显示，治疗中期饮酒可预测药物组的焦虑随着时间的推移而减少。
结论：研究结果表明，亚临床焦虑对AUD治疗后一年内饮酒的影响。基线焦虑症状可能会影响治疗过程中的饮酒行为。研究结果表明，即使对于患有共病焦虑症的个体，也有必要在AUD治疗中更多地关注负面影响。
